Metformin may improve outcomes in patients with non-small cell lung cancer (NSCLC) who are overweight or obese, according to a study published in the Journal of the National Cancer Institute.
Metformin may improve outcomes in patients with non-small cell lung cancer (NSCLC) who are overweight or obese, according to a study published in the Journal of the National Cancer Institute.
www.cancertherapyadvisor.com
Metformin May Improve RFS, OS in NSCLC Patients Who Are Overweight or Obese
The study showed that metformin use was associated with improvements in overall survival (OS) and recurrence-free survival (RFS) for overweight and obese patients who had undergone lobectomy. Researchers also found that metformin was associated with longer progression-free survival (PFS) in overweight NSCLC patients treated with immune checkpoint inhibitors (ICIs).